Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomePreferred Dividend PaymentsProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Cardiff Oncology (CRDF) Restructuring Costs (2016 - 2018)

Cardiff Oncology (CRDF) has disclosed Restructuring Costs for 3 consecutive years, with $421351.0 as the latest value for Q3 2018.

  • Quarterly Restructuring Costs rose 1006.68% to $421351.0 in Q3 2018 from the year-ago period, while the trailing twelve-month figure was $421351.0 through Sep 2019, down 63.0% year-over-year, with the annual reading at $664686.0 for FY2018, 69.43% down from the prior year.
  • Restructuring Costs hit $421351.0 in Q3 2018 for Cardiff Oncology, up from $243335.0 in the prior quarter.
  • In the past five years, Restructuring Costs ranged from a high of $1.7 million in Q1 2017 to a low of -$46472.0 in Q3 2017.
  • Historically, Restructuring Costs has averaged $514128.7 across 3 years, with a median of $421351.0 in 2018.
  • Biggest five-year swings in Restructuring Costs: tumbled 40.0% in 2017 and later skyrocketed 6493.46% in 2018.
  • Year by year, Restructuring Costs stood at $790438.0 in 2016, then crashed by 40.0% to $474251.0 in 2017, then fell by 11.15% to $421351.0 in 2018.
  • Business Quant data shows Restructuring Costs for CRDF at $421351.0 in Q3 2018, $243335.0 in Q2 2018, and $474251.0 in Q4 2017.